ConvaTec expands its USD 200 million buyback of ConvaTec stock
Published on 10/06/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ConvaTec (ISIN GB00BD3VFW73) expanded its previously announced USD 200 million share buyback with a tranche covering 1,348,440 ordinary shares. The Globe and Mail reported the purchases on October 6, 2026, covering trades executed between September 28 and October 2. At Lang & Schwarz, ConvaTec stock was trading at EUR 2.59 on October 6, 2026 at 2:06 p.m. CEST, unchanged from the prior close of EUR 2.59.
Buyback lifts treasury holdings
The latest purchases increased ConvaTec's treasury stock to 133,813,259 shares and left 1,915,976,300 ordinary shares in issue, according to The Globe and Mail. The reduced free float changes the denominator used when shareholders assess voting-rights disclosures, while the buyback also gives the company a direct way to return capital.
The program is large relative to the latest tranche. The USD 200 million ceiling covers a continuing capital-allocation plan, whereas the October update concerned 1,348,440 shares and did not change the stated maximum.
Product launches set the next test
ConvaTec's operating story is shifting toward product-led growth. In an interview published October 5, 2026, MedTech Dive reported that CEO Jonny Mason is targeting sales growth of 6 percent to 8 percent next year as the group launches new products across all four categories.
The same interview said ConvaTec launched eight products between 2022 and 2025 and plans eight more in 2026 and 2027. Infusion care is expected to grow at a double-digit rate from next year, giving investors a measurable test of whether research and development spending is translating into demand.
Analyst target stays above price
Barclays maintained a Buy rating and a GBP 3.00 price target in a report dated October 1, 2026, according to Markets Insider. The target is stated in pounds because it refers to the London listing, while the reference quote here remains the euro price from Lang & Schwarz.
ConvaTec stock holds at EUR 2.59
The London-listed medical products group combines capital returns with a product pipeline that includes wound care, ostomy care, continence care and infusion care. Its next execution marker is the planned product rollout, while the buyback provides a separate, dated shareholder-return measure.
At Lang & Schwarz, ConvaTec stock was trading at EUR 2.59 on October 6, 2026 at 2:06 p.m. CEST, with a change of 0.00 percent versus the Lang & Schwarz prior close of EUR 2.59 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of ConvaTec stock.
ConvaTec stock facts
- Company: ConvaTec Group Plc
- ISIN: GB00BD3VFW73
- Ticker: CTEC
- Primary exchange: London Stock Exchange
- Price Lang & Schwarz (as of October 6, 2026, 2:06 p.m. CEST): EUR 2.59
- Change versus prior close: 0.00 percent
- Prior close Lang & Schwarz (October 5, 2026): EUR 2.59
- Sector / Industry: Health Care / Medical Devices
